Slovenian Slovenian
en Englishaf Afrikaanssq Albanianar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbg Bulgarianca Catalanzh-CN Chinese (Simplified)zh-TW Chinese (Traditional)hr Croatiancs Czechda Danishnl Dutchet Estoniantl Filipinofi Finnishfr Frenchgl Galicianka Georgiande Germanel Greekht Haitian Creoleiw Hebrewhi Hindihu Hungarianis Icelandicid Indonesianga Irishit Italianja Japaneseko Koreanlv Latvianlt Lithuanianmk Macedonianms Malaymt Malteseno Norwegianfa Persianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesecy Welshyi Yiddish

Zadnje novice

EMA potrdila novo vlogo Biomarina za odobritev zdravila Roctavian

 

BioMarin ponovno daje gensko terapijo z roktavianom v odobritev EU

 

Poskus faze 1/2 za preizkus ASC618, genska terapija za hemofilijo A

 

FDA prijava za UniQure, genska terapija hemofilije B CSL, načrtovana za začetek leta 2022

 

Nazaj na vrh
Image

Please enable the javascript to submit this form

O nas

Podprto s štipendijami za izobraževanje Bayer, BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics in uniQure, Inc.

Bistveni SSL